Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
Clinical Pharmacokinetics · 2025
DOI: 10.1007/s40262-025-01513-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Zhiteng Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Acetylgalactosamine, Apolipoprotein C-III, Models, Biological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Gates Foundation, Capital's Funds for Health Improvement and Research, Foundation of State Key Laboratory of Vascular Homeostasis and Remodeling of Peking University.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: The emerging N-acetylgalactosamine-small interfering RNA (GalNAc-siRNA) conjugates lead the way for liver-targeting delivery to exert gene-silencing therapeutic effects. To facilitate the drug development of GalNAc-siRNA, further detailed understanding of the key modality-specific mechanisms underlying the temporal discordance between pharmacokinetics and pharmacodynamics and how these processes can be extrapolated from animals to humans is needed. METHODS: A mechanistic minimal physiologically based pharmacokinetic/pharmacodynamic (mPBPK-PD) model for an investigational new apolipoprotein C-III (APOC3)-silencing GalNAc-siRNA (RBD5044) was developed using available pharmacokinetic/pharmacodynamic (PK/PD) data. The aim was to explore hepatic-targeting delivery processes, the PK/PD relationship, and interspecies translation. RESULTS: First, multiple PK/PD datasets from mice were satisfactorily fitted using the mPBPK-PD model. Second, we translated the mice model to the monkey model, validated it, and then extrapolated from mice and monkeys to humans to simulate the PK/PD characteristics. We then mechanistically summarized and proposed the essential in vivo delivery processes of GalNAc-siRNA after subcutaneous administration (termed "ADUEB": Absorption [into system circulation], Disposition [distribution to liver target and elimination], Uptake [into hepatocytes], Escape [from endosome and lysosome compartments], and Binding [with argonaute2 to form RNA-induced silencing complex]). The targeting delivery coefficients of these processes achieved with the model using RBD5044 and the published data of another GalNAc-siRNA (fitusiran) quantitatively reflected the delivery efficiency and rate-limiting factors in targeted hepatocytes. CONCLUSION: This study successfully constructed the mPBPK-PD model and conducted interspecies extrapolation for a GalNAc-siRNA targeting APOC3. Promising quantitative insights into a hepatic-targeted GalNAc-siRNA delivery system are provided to characterize the unique temporal disconnection of PK/PD properties and evaluate the key in vivo delivery processes. It will promote model-informed strategies and quantitative mechanistic understanding to support efficient drug development, evaluation, and clinical application of this modality in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. sl_ongoing@sina.cn.
- Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital Beijing, Beijing, 100191, China. sl_ongoing@sina.cn.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. yzhen502@126.com.
- Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital Beijing, Beijing, 100191, China. yzhen502@126.com.
ORCID-Profile: Dongyang Liu
Förderung
- Gates Foundation
- Capital's Funds for Health Improvement and Research
- Foundation of State Key Laboratory of Vascular Homeostasis and Remodeling of Peking University
- Bill & Melinda Gates Foundation
Zitieren
APA
Tian, Z., Luo, H., Chu, Y., Liu, Y., Gao, S., Song, L., Yang, Z., & Liu, D. (2025). Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01513-4
Vancouver
Tian Z, Luo H, Chu Y, Liu Y, Gao S, Song L, et al. Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01513-4
BibTeX
@article{Tian2025,
author = {Tian, Zhiteng and Luo, Hui and Chu, Yantao and Liu, Yanhong and Gao, Shan and Song, Ling and Yang, Zhenzhen and Liu, Dongyang},
title = {Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model},
journal = {Clinical Pharmacokinetics},
year = {2025},
doi = {10.1007/s40262-025-01513-4}
}
EUVIMED